What is DiogenX?
DiogenX is dedicated to discovering and developing innovative biologics to address the needs of millions of diabetic patients globally. The company's lead program, stemming from Dr. Patrick Collombat’s research, targets beta-cell failure by stimulating functional recovery. This novel mechanism aims to rebalance glucose/insulin homeostasis, offering a unique therapeutic solution for diabetes management. The recent strategic investment signifies a critical juncture for the company as it advances its preclinical pipeline.
How much funding has DiogenX raised?
DiogenX has raised a total of $30.3M across 1 funding round:
Series A
$30.3M
Series A (2023): $30.3M with participation from Omnes Capital, JDRF T1D Fund, Eli Lilly and Company Pvt, and Boehringer Ingelheim Venture Fund
Key Investors in DiogenX
Omnes Capital
Omnes Capital is a European private equity firm focused on energy transition and deeptech innovation, managing over 6.7 billion euros and supporting high-performing companies.
JDRF T1D Fund
The T1D Fund is a venture impact fund dedicated to accelerating treatments, prevention, and cures for Type 1 Diabetes, investing in innovative therapies and reinvesting all returns.
Eli Lilly and Company Pvt
Eli Lilly and Company Pvt, an Indian subsidiary of the global biopharmaceutical giant, specializes in advanced treatment options for chronic diseases including diabetes.
What's next for DiogenX?
With this recent strategic backing, DiogenX is poised to accelerate the development of its promising therapeutic programs. The enterprise-level funding will likely support further preclinical studies, potential IND-enabling activities, and the expansion of its research and development team. This capital infusion is instrumental in advancing DiogenX's mission to provide meaningful clinical benefits and novel treatment options for individuals affected by diabetes, positioning the company for future growth and potential partnerships within the biopharmaceutical sector.
See full DiogenX company page
